Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
Non-randomised trial
OA: bronze
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study investigated how aromatase inhibitors affect the estrogen surge observed when gonadotropins are administered to patients already undergoing treatment with GnRH agonists.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This was a preliminary study to determine the effect of aromatase inhibitors in preventing the flare induced by GnRH agonist (GnRH-a) in women with endometriosis (n = 9) or leiomyomata (n = 4) who were given letrozole on the first 5 days of the GnRH-a therapy. Serum LH and FSH levels showed the typical flare 1 day after the injection of the GnRH-a; however, E(2) declined immediately after letrozole administration and was notably suppressed at 1, 2, and 4 days after GnRH-a. No patients complained of clinical symptoms typical of the GnRH-a flare phenomenon.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (26)
- A review of current management of endometriosis in 2006: an evidence-based approach via openalex
- Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist via openalex
- Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis via openalex
- GnRH analogs: options for endometriosis-associated pain treatment via openalex
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders via openalex
- Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2(10)]LH-RH ethylamide via openalex
- Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study] via openalex
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain via openalex
- W173875890 via openalex
- W116864337 via openalex
- W2111301534 via openalex
- W2130005791 via openalex
- W2159608759 via openalex
- W2165684716 via openalex
- W2343033730 via openalex
- W6602628479 via openalex
- W6606967296 via openalex
- W1569246512 via openalex
- W6683236057 via openalex
- W1967877758 via openalex
- W1983655425 via openalex
- W2009298269 via openalex
- W2025609858 via openalex
- W2029727633 via openalex
Cited by (19)
- Guideline No. 468: Clinical Management of Endometriosis 2026
- Lignes directrices de pratique clinique n° 468 : Prise en charge clinique de l'endométriose 2026
- Endometriosis: A Narrative Review 2024
- Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study 2024
- Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix 2023
- Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study 2022
- Uso de inhibidores de la aromatasa en el tratamiento del dolor pélvico asociado a endometriosis: revisión sistemática 2021
- Role of medical treatment of endometriosis 2021
- Uso de inhibidores de la aromatasa en el tratamiento del dolor pélvico asociado a endometriosis: revisión sistemática 2021
- Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure 2019
- Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis 2018
- A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF 2018
- New developments in the medical treatment of endometriosis 2017
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
- Medical treatment of ureteral obstruction associated with ovarian remnants and/or endometriosis: report of three cases and review of the literature 2014
- Evidence-based long-term management of endometriosis: Medical therapy and treatment of infertility 2011
- Use of aromatase inhibitors in gynecology 2010
- [Treatment of endometriosis by aromatase inhibitors: efficacy and side effects] 2010
- Aromatase inhibitors: potential reproductive implications 2009
Source provenance
- europepmc
- last seen: 2026-10-26T06:15:05.866214+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:05:50.299847+00:00
License: CC0
· commercial use OK